COVID-19 (Coronavirus) Update

A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer

Protocol No
SWOG-LUNGMAP-S1900B
Principal Investigator
Smitha Menon
Phase
II
Summary
The purpose of this study is to test the good and bad effects of the drug called LOXO-292. LOXO-292 could shrink your cancer, but it could also cause side effects, which are described in the risks section below. The study doctors hope to learn if the treatment will shrink your tumor. Another purpose of this study is for the study doctors to learn if a biomarker test for RET fusions is helpful in assigning treatment. LOXO-292 is not approved by the FDA for use in advanced non-small cell lung cancer. There will be up to 124 people taking part in this study
Description
Testing the Use of Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer
Participating Institutions
Froedtert Hospital
Froedtert Menomonee Falls Hospital
Froedtert West Bend Hospital
Status
OPEN TO ACCRUAL
Share This: